Brazil's RedeRio to hone key techs policy:
This article was originally published in Clinica
RedeRio, an R&D network centred in Rio de Janeiro state, is Brazil's latest initiative to hone policy in key areas of medtech use. The network comprises leading R&D institutes and hospitals in the areas of orthopaedics (INTO), cardiology (INCL), cancer (INCA) and infant-maternal care (such as Hospital de Ipanema). Its first task will be to "assess the potential of the installations and equipment of the hospitals and institutes involved", said the health ministry. RedeRio's input will be used to support policy affecting the national delivery of so-called mid- to high-complexity care, currently worth an estimated R$17bn (US$7.9m) of the R$22bn budgeted for primary care. Cardiology high-complexity care alone has a R$800m budget.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.